Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer.

Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer. Int J Cancer. 2018 09 01; 143(5):1162-1175.

View in: PubMed

subject areas

Alternative Splicing
Alternative Splicing
Animals
Animals
Antineoplastic Agents
Antineoplastic Agents
Apoptosis
Apoptosis
Biomarkers, Tumor
Biomarkers, Tumor
Carcinoma, Renal Cell
Carcinoma, Renal Cell
Cell Movement
Cell Movement
Cell Proliferation
Cell Proliferation
Cell Transformation, Neoplastic
Cell Transformation, Neoplastic
Drug Resistance, Neoplasm
Drug Resistance, Neoplasm
Epithelial-Mesenchymal Transition
Epithelial-Mesenchymal Transition
Follow-Up Studies
Follow-Up Studies
Humans
Humans
Intracellular Signaling Peptides and Proteins
Intracellular Signaling Peptides and Proteins
Kidney Neoplasms
Kidney Neoplasms
Male
Male
Mice
Mice
Mice, Nude
Mice, Nude
Neoplastic Stem Cells
Neoplastic Stem Cells
Prognosis
Prognosis
RNA, Small Interfering
RNA, Small Interfering
Survival Rate
Survival Rate
Tumor Cells, Cultured
Tumor Cells, Cultured
Xenograft Model Antitumor Assays
Xenograft Model Antitumor Assays

authors with profiles

Courtney Wayne Houchen
Dongfeng Qu
Michael Stuart Bronze
William Lee Berry